Economic Burden of Neurological diseases in Europe
“Economic Burden of Neurological diseases in Europe” project was launched during 2021 and is run by the EAN and lead by Prof. Siebert from the University for Health Sciences (Austria) and Prof. Dodel from the Duisburg Essen University (Germany).
This project is overseen at the EAN by Prof. Boon (EAN President), Prof. Bassetti (EAN Past President) and Prof. Berger (EAN Scientific Committee Chair).
The study intends to evaluate the cost of illness of neurological disorders in order to assess their socio-economic burden. The research is methodologically based on a systematic review approach and a meta-analysis of the epidemiological and health economic literature.
Its outcomes will include, among others, a detailed report of the literature search results, the methodology for summarizing and extrapolating available data, and the resulting estimates of prevalence, burden and cost by country and diagnosis.
In this now new study, diseases already considered for all European countries were:
- Ischemic stroke
- Intracerebral hemorrhage
- Alzheimer's disease and other dementias
- Parkinson’s disease and other movement disorders
- Meningitis/ Encephalitis/ Meningoencephalitis
- Idiopathic epilepsy
- Multiple sclerosis
- Tension-type headache
- Brain and other nervous system cancer
- Traumatic brain injuries
- Myopathies and other neuromuscular disorders
- ALS and other motor neuron diseases
- Neurofunctional disorders
- Sleep-wake disorders
This project has been recently awarded an important grant by the LINF (Lundbeck International Neuroscience Foundation). This grant is awarded to international endeavors that regard the prevalence, burden and economic costs of brain disorders.
By means of the awarded grant, an independent part of this project (in charge of Prof. Dodel and his team) is now also expected to cover all countries around the world and additionally it will include as part of their analysis, the main mental health disorders. Furthermore, the effects that COVID-19 has on brain disorders will also be considered.